Effect of silymarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis C patients: a miniature clinical trial
Even though it is not considered a fat-burning peptide, some researchers and healthcare providers believe it may indirectly support weight management through several mechanisms
If approved for the treatment of obesity, orforglipron could provide a convenient alternative for the millions of individuals living with obesity around the globe to continue their long-term health journey." In the study, orforglipron met the primary endpoint of superior percent maintenance of body weight reduction compared to placebo, among SURMOUNT-5 participants who previously reached a body weight plateau
For now, Eli Lilly could continue to experience elevated growth, such as the 56% revenue growth reported last quarter, with the launch of new weight-loss and diabetes drugs helping to sustain the high growth driven by Zepbound's and Mounjaro's "out of the gate success." Meanwhile, Novo Nordisk, despite recent success with its Wegovy pill, reported negative adjusted sales growth last quarter, with full-year guidance calling for further declines